Chemical vs. drugs (Part 2): How do you discriminate? / More on halicin

Dear All (wonkish note alert!),

The recent newsletter on chemicals, drugs, and halicin (link, see also a follow-up newsletter here) generated significant discussion and new insights that I thought I would share in a follow-up newsletter. Our theme in Part 2 is “Trust, but verify!” 

Let’s start by considering comments on the newsletter. A number of you wrote to add support for the idea that the specific antibacterial candidate identified by Stokes et al. (link, SU3227/halicin) is very unlikely to be a safe systemic human medicinal:

  • As noted in the first newsletter, c-Jun N-terminal kinases are involved in many critical biological pathways and inhibitors of same (such as SU3227) would need to be highly selective.
  • Indeed, the idea of seeking a novel antibacterial from a screen of human drug candidates from other therapy areas must by definition find compounds with effects on some aspect of human biology. Thus, such compounds would have two diverse activities (the antibacterial effect as well as the intrinsic effect on some human system) and hence be at risk for being toxic depending on the nature of the effect on that human system. It might be possible to make derivatives that would lose those effects, but the compound series starts with that liability.
  • Finally, and going on a limb a bit as I am not a chemist, the specific molecule (see its structure as the inset to Figure 2H from the paper) contains a nitro group attached to an aromatic ring, something that I’ve been taught is a mutagencity risk (link to a comment by Derek Lowe entitled “I Want A New Nitro” and link to a longer in-depth 2019 paper by Kepali et al. in J Med Chem).

So, SU3227/halicin might be topical medicinal (and they do show that in their paper) but it is unlikely to go further than that for this particular molecule. That said, the comments also noted that the idea of applying machine learning to antibiotic discovery is noteworthy and we all hope that continued work will refine the approach and identify useful new areas of chemical space. 

So, we now come to the deeper question that is the focus of this newsletter: How can we distinguish toxic chemicals from possible new antibacterial drugs? And this may not be easy as we are asking something special of these molecules: we want them to kill a living organism, but to do so selectively!  So, there is a perspective from which we may need to be willing to consider molecules that carry some risk. That noted, the quip “It’s easy to kill bacteria — steam, fire, and bleach are consistently effective — but those aren’t drugs!” provides no help at all with finding a path forward. For example, what about the further 23 candidate antibacterial molecules identified by their screening of the 1.5 billion compound ZINC15 database (Figure 6D)? Those compounds do have antibacterial activity — might they be drugs?

There are no perfect tools here and the problem is complicated by the fact that antibacterial compounds are often not “drug-like” from the perspective of Lipinski’s Rule of 5 (link). Reinforcing the notion that antibiotics often defy typical medicinal chemistry rules, some antibiotics even have reactive elements (e.g., fosfomycin is an epoxide). So, what can be done? Well, we do have some practical suggestions to hand. 

Our initial Chemical-vs-Drug signpost comes from the Instructions to Authors for Antimicrobial Agents and Chemotherapy (AAC, link). As part of guideline #6 on the first page of the instructions, we have:

  • “Manuscripts dealing with novel small molecular antimicrobials must provide at least some data showing that the proposed new agents or scaffolds have the potential to become therapeutic agents.
  • “Appropriate demonstrations will vary but generally should be some combination of data on physical properties (solubility, protein binding, log P [logarithm of the ratio of the concentrations of un-ionized solutes in solvents]), pharmacological properties (Caco2 predictions of bioavailability, pharmacokinetics in an animal species), or tolerability (mammalian cell toxicity, likelihood of hepatic metabolism, potential for receptor interactions, potential for human ERG liability).
  • “Initial presentations of compounds are not expected to address all these areas but rather to show an appropriate initial subset.
  • “For example, the first publication of a novel compound or compound series might address selected physical properties plus mammalian cell toxicity.
  • “Subsequent publications are expected to add progressively to the proof of the agent’s therapeutic potential.
  • “For cationic peptide molecules, an additional expectation is that the molecule demonstrates a profile that is distinct from previously reported similar molecules and that it demonstrates reasonable pharmacokinetics or credible efficacy in an in vivo tissue model of infection (e.g., thigh or lung).”

Our second Chemical-vs-Drug signpost comes from the pragmatic screening approach for novel antibiotics that is being implemented by CO-ADD (https://www.co-add.org/, Community for Open Antimicrobial Drug Discovery), a global open-access screening initiative. Launched in February 2015 and funded for nearly 5 years by the Wellcome Trust supplemented by support from the Institute for Molecular Bioscience (UQ IMB) and The University of Queensland (UQ), CO-ADD provides free antimicrobial screening with no encumbrances (in particular, no impact on IP with the proviso that structures should ultimately be published in CO-ADD’s database) for compound collections from any interested academic researcher..

To date, CO-ADD has screened about 300,000 compounds from 47 countries by following this 3-step process (https://www.co-add.org/content/free-screening):

  • Step 1: Primary Screening
    • In the primary screening we test compound libraries against key ESKAPE pathogens, E. coli, K. pneumoniae, A. baumannii, P. aeruginosa, S. aureus (MRSA), as well as the fungi C. neoformans and C. albicans.
    • The screen will be at a single concentration (32 µg/mL) and will provide initial activity data to select compounds for further more detailed screening.  
  • Step 2: Hit Confirmation
    • Active compounds from the primary screening will be tested in dose response antimicrobial assays to confirm their activity.
    • Active compounds will be screened for adverse effects, such as cytotoxicity, critical micelle concentration and membrane depolarization, as well as for their purity.
    • The Hit confirmation process will evaluate the basic drug qualities of actives, and which of the actives have the best potential for further development.    
  • Step 3: Hit Validation
    • The next step of the CO-ADD process is to test the hit against a broader panel of microbes with multidrug-resistant (MDR) and pan-resistant bacterial strains and clinical isolates, with different co-factors (such as serum or lung surfactant).
    • The Hit validation will also include initial ADMET screening, including haemolysis, microsome and plasma stability and protein binding.
    • In addition, structural analogues could be included to evaluate any structure-activity relationship.

If you look at this sequence of tests, it is readily seen to parallel the ideas in AAC’s suggestions for initial data. Testing vs. both bacteria and fungi in Step 1 is a simple way to spot general toxins: if something kills both prokaryotes and eukaryotes, it is probably not a drug! Step 2 does simple tests to look for indiscriminate activity such as being a detergent. Finally, things get serious in Step 3 with a broader look at the activity of the compound series.

As a demonstration of the potentially utility of this approach to mine novel chemical space, CO-ADD has recently published a paper (Frei et al., link) in which they observe that metal-containing compounds have an unusually high validated hit rate. The authors conclude, “This work reveals the vast diversity that metal-containing compounds can bring to antimicrobial research. It is important to raise awareness of these types of compounds for the design of truly novel antibiotics with potential for combating antimicrobial resistance.”

I’m sure that the real chemists in our community can suggest other ideas (e.g., the idea of PAINS, link), but I think that’s enough for a general path. Putting it all together, the core idea is that we always need to remember that “It’s easy to kill bacteria — steam, fire, and bleach are consistently effective” and balance this with the adage “Trust, but verify.” 

Many thanks to all who wrote! All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Operating Partner, Advent Life Sciences. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://amr.solutions/blog/

Current funding opportunities:

  • Open now through 28 Feb 2020: FDA call for applications to create rabbit models of ventilator-associated bacterial pneumonia (VAP or VABP, depending on your preferred abbreviation) due to carbapenem-resistant strains of A. baumannii and P. aeruginosa. Go here for details.
  • Open now through 16 Mar 2020: CC4CARB, NIAID’s call for applications to fund an innovative Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB). Go here for details.
  • Open now through 9 Apr 2020: NIAID Broad Agency Announcement (BAA) soliciting contract proposals for preclinical and clinical development of vaccines, therapeutic, and diagnostics for microbial pathogens. Go here for more.
  • Dates for the 2020 funding rounds for Novo REPAIR Impact Fund will be announced May 2020. Go here for current details.
  • 2020 funding rounds for CARB-X have not been announced.


Upcoming meetings of interest to the AMR community:

  • Unclear dates. University of Sheffield (UK). Applications are being taken for a new 1-year (full-time) or 2-year (part-time) Masters of Science course in Antimicrobial Resistance. The program appears to start Fall 2020. The course webpage is here. Further details when I have them!
  • 26-27 Feb 2020 (Washington, DC): US PACCARB public meeting. Go here for details.
  • 27 Feb 2020 (1700-1830 CET, online): GARDP-sponsored webinar entitled “PK/PD murine infection models: Focus on study elements, variability, and interpretation of results.” Go here to register.
  • 1-6 Mar 2020 (Il Ciocco, Tuscany, Italy): Gordon Research Conference (GRC) on Antibacterial Discovery and Development: “Now is the time to re-boot antibiotic R&D before it’s too little, too late.” Go here for details.
  • 5 Mar 2020 (FDA, White Oak Campus, 8.30a-5.00p EST): FDA workshop entitled “Advancing Animal Models for Antibacterial Drug Development.” FR notice is here and registration is here. The workshop will be webcast.
  • 12-13 Mar 2020 (Basel): BEAM-, Novo REPAIR-, CARB-X-, DZIF-, ND4BB-, ENABLE-supported (among a long list!) Conference on Novel Antimicrobials and AMR Diagnostics. Details are here, poster deadline is 12 Dec 2019.  
  • 16-17 Mar 2020 (London): BSAC Spring Conference entitled: “Bridging the gap between science, policy and effective antimicrobial use.” Go here for details. 
  • [UPDATED – REGISTRATION IS NOW OPEN] 20 Mar 2020 (Boston, MA): 7th annual BAARN (Boston Area Antimicrobial Resistance Network) Meeting. Chaired by Lawson Ung and Michael Gilmore, talks start at 9am and end with a reception at the Harvard Museum of Natural History. Go here to register; you can also contact Lawson Ung (lawson_ung@meei.harvard.edu) for other inquiries.
  • 26-30 Mar 2020 (Atlanta, GA): CDC- and SHEA-sponsored 6th International Conference on Healthcare Associated Infections. Go here for details.
  • 30 Mar 2020 (everywhere): Deadline for applications for the Molecular Mycology pathogenesis course at Marine Biological Laboratory, Woods Hole. Now in its 24th year, the hands-on residential course runs 17 July to 2 Aug and gets rave reviews. Go here for more.
  • 9 Apr 2020 (everywhere): Final date for applications for NIAID/DMID call (link) for AMR-related vaccines, therapeutics, and diagnostics.
  • [NEW] 17 Apr 2020 (Paris): Pre-ECCMID workshop entitled “Machine Learning for Clinical Microbiology”. Go here for details. 
  • 18-21 Apr 2020 (Paris): Annual ECCMID meeting (#30)
  • 25-30 May 2020 (Rotterdam), Annual ESPID meeting (European Society for Pediatric ID, #38)
  • 18-22 Jun 2020 (Chicago), ASM Microbe 2020. Go here for details.
  • 27-28 Jun 2020 (Bryant University, Rhode Island): Drug Resistance Gordon Research Seminar entitled “Mechanisms and Approaches to Overcoming Drug Resistance in Cancer, Infectious Disease and Agriculture” for graduate students and postdoctoral scientists. Go here for details … this immediately precedes the GRC listed just next
  • 28 Jun-3 Jul 2020 (Bryant University, Rhode Island): Gordon Research Conference (GRC) entitled “Strategies to Disrupt Drug Resistance in Infectious Disease, Cancer and Agriculture.” Go here for details.
  • 1-4 Sep 2020 (Dublin): Annual ASM-ESCMID Conference on Antibiotic Development #5! Mark your calendar now and go here for details.
  • 9-10 Sep 2020 (Washington, DC): US PACCARB public meeting. Go here for details.
  • 22-25 Sep 2020 (Albuquerque, New Mexico): Biannual meeting of the MSGERC (Mycoses Study Group Education and Research Consortium). Save-the-date announcement is here, details to follow.
  • 17-25 Oct 2020 (Annecy, France): Interdisciplinary Course on Antibiotics and Resistance (ICARe). This is a soup-to-nuts residential course on antibiotics, antibiotic resistance, and antibiotic R&D. The course is very intense, very detailed, and gets rave reviews. The date is set for 2020 and the program will ultimately appear here. Registration is limited to 40 students and opens 15 Mar 2020.
  • 10-13 Apr 2021 (Vienna): Annual ECCMID meeting (#31)
  • 3-7 Jun 2021 (Anaheim), ASM Microbe 2021. Go here for details.

Share

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on whatsapp
Share on reddit

In Praise of Non-Inferiority

Dear All (wonkish but intended for everybody to read and absorb): There’s been a lot of recent discussion about “lessons learned from COVID-19.” Indeed, there are many valuable points: global cooperation, preparedness, supply chains, and so forth. As an example, I note the 17 Sep 2020 communique from the G20 Health Ministers (link): it was heavily

FDA and EMA regulatory updates / Fireside chat during the 4th AMR Conference

Dear All (lots and lots of wonkish detail here, be sure your blood caffeine level is adequate!), During the 24-28 Aug 2020 BEAM Alliance-sponsored AMR Conference (go here or see below my signature for more), I had the opportunity on 27 August to chat with Sumati Nambiar (FDA) and Marco Cavaleri (EMA) about ongoing regulatory activities. The

Treating resistant Gram-negatives: IDSA provides pragmatic expert advice

Dear All, IDSA (Infectious Diseases Society of America) have today released an eagerly awaited new guidance document on treating infections due to resistant Gram-negative bacteria (link). The thing that makes this document unusual is that it is an expert guidance rather than a formal guideline. Although there is value in formal guidelines that carefully review

New antibiotics are not being registered or sold in Europe in a timely manner

Dear All (and with thanks to Kevin for leading the charge on this newsletter), While listening to last week’s BEAM-sponsored AMR Conference (really a wonderful conference, thank you Team BEAM, go here to listen to the sessions), we tumbled onto a really, really disturbing trend: New antibiotics are not being registered or sold in Europe in

Scroll to Top